Cargando…

Oxaliplatin-induced haematological toxicity and splenomegaly in mice

PURPOSE: Haematological toxicities occur in patients receiving oxaliplatin. Mild anaemia (grade 1–2) is a common side effect and approximately 90% of recipients develop measurable spleen enlargement. Although generally asymptomatic, oxaliplatin-induced splenomegaly is independently associated with c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lees, Justin G., White, Daniel, Keating, Brooke A., Barkl-Luke, Mallory E., Makker, Preet G. S., Goldstein, David, Moalem-Taylor, Gila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467301/
https://www.ncbi.nlm.nih.gov/pubmed/32877416
http://dx.doi.org/10.1371/journal.pone.0238164
_version_ 1783577983173263360
author Lees, Justin G.
White, Daniel
Keating, Brooke A.
Barkl-Luke, Mallory E.
Makker, Preet G. S.
Goldstein, David
Moalem-Taylor, Gila
author_facet Lees, Justin G.
White, Daniel
Keating, Brooke A.
Barkl-Luke, Mallory E.
Makker, Preet G. S.
Goldstein, David
Moalem-Taylor, Gila
author_sort Lees, Justin G.
collection PubMed
description PURPOSE: Haematological toxicities occur in patients receiving oxaliplatin. Mild anaemia (grade 1–2) is a common side effect and approximately 90% of recipients develop measurable spleen enlargement. Although generally asymptomatic, oxaliplatin-induced splenomegaly is independently associated with complications following liver resection for colorectal liver metastasis and separately with poorer patient outcomes. Here, we investigated oxaliplatin-induced haematological toxicities and splenomegaly in mice treated with escalating dosages comparable to those prescribed to colorectal cancer patients. METHODS: Blood was analysed, and smears assessed using Wright-Giemsa staining. Paw coloration was quantified as a marker of anaemia. Spleen weight and morphology were assessed for abnormalities relating to splenomegaly and a flow cytometry and multiplex cytokine array assessment was performed on splenocytes. The liver was assessed for sinusoidal obstructive syndrome. RESULTS: Blood analysis showed dose dependent decreases in white and red blood cell counts, and significant changes in haematological indices. Front and hind paws exhibited dose dependent and dramatic discoloration indicative of anaemia. Spleen weight was significantly increased indicating splenomegaly, and red pulp tissue exhibited substantial dysplasia. Cytokines and chemokines within the spleen were significantly affected with temporal upregulation of IL-6, IL-1α and G-CSF and downregulation of IL-1β, IL-12p40, MIP-1β, IL-2 and RANTES. Flow cytometric analysis demonstrated alterations in splenocyte populations, including a significant reduction in CD45+ cells. Histological staining of the liver showed no evidence of sinusoidal obstructive syndrome but there were signs suggestive of extramedullary haematopoiesis. CONCLUSION: Chronic oxaliplatin treatment dose dependently induced haematological toxicity and splenomegaly characterised by numerous physiological and morphological changes, which occurred independently of sinusoidal obstructive syndrome.
format Online
Article
Text
id pubmed-7467301
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-74673012020-09-11 Oxaliplatin-induced haematological toxicity and splenomegaly in mice Lees, Justin G. White, Daniel Keating, Brooke A. Barkl-Luke, Mallory E. Makker, Preet G. S. Goldstein, David Moalem-Taylor, Gila PLoS One Research Article PURPOSE: Haematological toxicities occur in patients receiving oxaliplatin. Mild anaemia (grade 1–2) is a common side effect and approximately 90% of recipients develop measurable spleen enlargement. Although generally asymptomatic, oxaliplatin-induced splenomegaly is independently associated with complications following liver resection for colorectal liver metastasis and separately with poorer patient outcomes. Here, we investigated oxaliplatin-induced haematological toxicities and splenomegaly in mice treated with escalating dosages comparable to those prescribed to colorectal cancer patients. METHODS: Blood was analysed, and smears assessed using Wright-Giemsa staining. Paw coloration was quantified as a marker of anaemia. Spleen weight and morphology were assessed for abnormalities relating to splenomegaly and a flow cytometry and multiplex cytokine array assessment was performed on splenocytes. The liver was assessed for sinusoidal obstructive syndrome. RESULTS: Blood analysis showed dose dependent decreases in white and red blood cell counts, and significant changes in haematological indices. Front and hind paws exhibited dose dependent and dramatic discoloration indicative of anaemia. Spleen weight was significantly increased indicating splenomegaly, and red pulp tissue exhibited substantial dysplasia. Cytokines and chemokines within the spleen were significantly affected with temporal upregulation of IL-6, IL-1α and G-CSF and downregulation of IL-1β, IL-12p40, MIP-1β, IL-2 and RANTES. Flow cytometric analysis demonstrated alterations in splenocyte populations, including a significant reduction in CD45+ cells. Histological staining of the liver showed no evidence of sinusoidal obstructive syndrome but there were signs suggestive of extramedullary haematopoiesis. CONCLUSION: Chronic oxaliplatin treatment dose dependently induced haematological toxicity and splenomegaly characterised by numerous physiological and morphological changes, which occurred independently of sinusoidal obstructive syndrome. Public Library of Science 2020-09-02 /pmc/articles/PMC7467301/ /pubmed/32877416 http://dx.doi.org/10.1371/journal.pone.0238164 Text en © 2020 Lees et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Lees, Justin G.
White, Daniel
Keating, Brooke A.
Barkl-Luke, Mallory E.
Makker, Preet G. S.
Goldstein, David
Moalem-Taylor, Gila
Oxaliplatin-induced haematological toxicity and splenomegaly in mice
title Oxaliplatin-induced haematological toxicity and splenomegaly in mice
title_full Oxaliplatin-induced haematological toxicity and splenomegaly in mice
title_fullStr Oxaliplatin-induced haematological toxicity and splenomegaly in mice
title_full_unstemmed Oxaliplatin-induced haematological toxicity and splenomegaly in mice
title_short Oxaliplatin-induced haematological toxicity and splenomegaly in mice
title_sort oxaliplatin-induced haematological toxicity and splenomegaly in mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467301/
https://www.ncbi.nlm.nih.gov/pubmed/32877416
http://dx.doi.org/10.1371/journal.pone.0238164
work_keys_str_mv AT leesjusting oxaliplatininducedhaematologicaltoxicityandsplenomegalyinmice
AT whitedaniel oxaliplatininducedhaematologicaltoxicityandsplenomegalyinmice
AT keatingbrookea oxaliplatininducedhaematologicaltoxicityandsplenomegalyinmice
AT barkllukemallorye oxaliplatininducedhaematologicaltoxicityandsplenomegalyinmice
AT makkerpreetgs oxaliplatininducedhaematologicaltoxicityandsplenomegalyinmice
AT goldsteindavid oxaliplatininducedhaematologicaltoxicityandsplenomegalyinmice
AT moalemtaylorgila oxaliplatininducedhaematologicaltoxicityandsplenomegalyinmice